Evidence map›Paper›PMID 41859044›Full record

ArticleBiomedical reports2026

Preliminary exploration of the role of CD8

Huachun Chen, Fakai Li, Jun Song, Sheng Wang, Hanwen Xu, Ruoya Lyu, Hui Zhang, Guiyuan Chen, Xiaoyu Wu, Mingxing Ding

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedical reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Huachun ChenDepartment of Respiratory and Critical Care Medicine, Jinhua Guangfu Tumor Hospital, Jinhua, Zhejiang 321001, P.R. China.
Fakai LiDepartment of Respiratory and Critical Care Medicine, Jinhua Guangfu Tumor Hospital, Jinhua, Zhejiang 321001, P.R. China.
Jun SongDepartment of Respiratory and Critical Care Medicine, Jinhua Guangfu Tumor Hospital, Jinhua, Zhejiang 321001, P.R. China.
Sheng WangDepartment of Science and Education, Jinhua Guangfu Tumor Hospital, Jinhua, Zhejiang 321001, P.R. China.
Hanwen XuDepartment of Respiratory and Critical Care Medicine, Jinhua Guangfu Tumor Hospital, Jinhua, Zhejiang 321001, P.R. China.
Ruoya LyuDepartment of Respiratory and Critical Care Medicine, Jinhua Guangfu Tumor Hospital, Jinhua, Zhejiang 321001, P.R. China.
Hui ZhangInstitute of Pharmacology, Jinhua Food and Drug Inspection and Testing Research Institute, Jinhua, Zhejiang 321002, P.R. China.
Guiyuan ChenNursing Faculty, Medical College of Jinhua University of Vocational Technology, Jinhua, Zhejiang 321007, P.R. China.
Xiaoyu WuDepartment of Respiratory and Critical Care Medicine, Jinhua Guangfu Tumor Hospital, Jinhua, Zhejiang 321001, P.R. China.
Mingxing DingMedical Molecular Biology Laboratory, Medical College of Jinhua University of Vocational Technology, Jinhua, Zhejiang 321007, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Globally, ~33% of patients with non-small cell lung cancer receiving anti-PD-1 antibody therapy may experience significant immune-related adverse events (irAEs). Among these, myocarditis is a rare but lethal irAE. The aim of the present study was to preliminarily explore the role of CD8

Indexed as

anti-PD-1CD8+ T cellimmune checkpoint inhibitorimmune-related adverse eventLewis lung carcinomamyocarditis

Identifiers

PMID41859044
PMCPMC12996858

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.